Haemonetics (NYSE:HAE) Posts Earnings Results, Misses Expectations By $0.01 EPS

Haemonetics (NYSE:HAE - Get Free Report) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01), Zacks reports. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Haemonetics updated its FY 2025 guidance to 4.500-4.700 EPS.

Haemonetics Price Performance

HAE traded up $1.17 on Monday, hitting $60.51. 2,349,898 shares of the company were exchanged, compared to its average volume of 1,000,911. The business's fifty day moving average is $76.38 and its 200 day moving average is $78.22. Haemonetics has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The firm has a market capitalization of $3.04 billion, a P/E ratio of 23.82, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39.

Wall Street Analysts Forecast Growth

HAE has been the subject of several recent research reports. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 target price for the company. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday. StockNews.com raised Haemonetics from a "hold" rating to a "buy" rating in a report on Friday. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the stock from $95.00 to $68.00 in a report on Friday. Finally, JMP Securities dropped their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.